Department of Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan,
Mod Rheumatol. 2013 Sep;23(5):904-12. doi: 10.1007/s10165-012-0760-4. Epub 2012 Sep 14.
The purpose of this study was to examine the treatment retention and efficacy of abatacept, the first member of a new class of biologic agents, in Japanese rheumatoid arthritis (RA) patients during clinical practice.
A retrospective multicenter study was conducted with patients who underwent abatacept therapy for 24 weeks (n = 143).
Patients at baseline had a mean age of 63.5 years, a mean disease duration of 11.3 years, and a mean disease activity score in 28 joints (DAS28) of 4.5. Overall retention of abatacept treatment was 83.2 % at 24 weeks, when 46.2 % of patients achieved DAS28-defined low disease activity (LDA; DAS28 <3.2) and 26.6 % achieved DAS28-defined remission (DAS28 <2.6). LDA was achieved in a significantly higher proportion of patients without prior biologics therapy compared to those with prior biologics (60.9 vs. 34.2 %, p = 0.001). There was no significant difference between patients with or without concomitant methotrexate (MTX) therapy (45.2 vs. 47.5 %).
Abatacept therapy appears to be highly effective and well tolerated during clinical treatment of RA. Abatacept was particularly effective in patients with no history of biologics use, and did not appear to be dependent on concomitant MTX therapy.
本研究旨在考察阿巴西普作为新型生物制剂的首个成员，在日本类风湿关节炎（RA）患者中的临床实践中的治疗保留率和疗效。
对接受阿巴西普治疗 24 周的患者（n=143）进行了回顾性多中心研究。
基线时，患者的平均年龄为 63.5 岁，平均病程为 11.3 年，28 个关节疾病活动度评分（DAS28）为 4.5。24 周时，阿巴西普治疗的总体保留率为 83.2%，46.2%的患者达到 DAS28 定义的低疾病活动度（DAS28<3.2），26.6%达到 DAS28 定义的缓解（DAS28<2.6）。与有既往生物制剂治疗的患者相比，无既往生物制剂治疗的患者达到 LDA 的比例显著更高（60.9%比 34.2%，p=0.001）。有或无伴随甲氨蝶呤（MTX）治疗的患者之间无显著差异（45.2%比 47.5%）。
阿巴西普治疗在 RA 的临床治疗中似乎具有高度有效性和良好耐受性。阿巴西普在无生物制剂治疗史的患者中尤其有效，且似乎不依赖于伴随的 MTX 治疗。
